Introduction {#Sec1}
============

Cannabis use is an important global public health issue, and a growing topic of controversy and debate^[@CR1],[@CR2]^. It is the most widely used illicit psychoactive substance in the world^[@CR3]^, and the potential medicinal and therapeutic benefits of cannabis and its main active ingredients tetrahydrocannabinol (THC) and cannabidiol (CBD) are gaining interest^[@CR4]--[@CR6]^. There is strong evidence to suggest that the heavy and prolonged use of cannabis may be associated with increased risk of adverse outcomes in a number of areas, including mental health (psychosis^[@CR7]--[@CR9]^, schizophrenia^[@CR10],[@CR11]^, depression^[@CR12],[@CR13]^) and illicit drug abuse^[@CR14]^.

Drug metabolism, drug response and drug addiction have known genetic components^[@CR15]^, and multiple genome-wide association studies (GWAS) have identified genes and allelic variants that are likely contributors to substance use disorders^[@CR16],[@CR17]^. There are aspects of cannabis use disorder that are heritable^[@CR18]--[@CR21]^, and several candidate loci for complex phenotypes such as lifetime cannabis use have recently been identified^[@CR3],[@CR22]^ that explain a proportion of the variance in cannabis use heritability. Complex phenotypes like these are influenced by multiple loci, each of which usually has a small individual effect size^[@CR23]^, and such loci are frequently located in non-coding regions of the genome^[@CR24],[@CR25]^, making their biological role difficult to elucidate.

Epigenetic mechanisms are involved in the interaction between the genome and environment; they respond to changes in environmental stimuli (such as diet, exercise, drugs), and act to alter chromatin structure and thus regulate gene expression^[@CR26]^. Epigenetic modifications, such as DNA methylation, contribute to complex traits and diseases^[@CR27],[@CR28]^. Methylation of cytosine residues within CpG dinucleotides is an important mechanism of variation and regulation in the genome^[@CR29]--[@CR32]^. Cytosine methylation, particularly in the promoter region of genes, is often associated with a decrease in transcription^[@CR33]^, and DNA methylation in the first intron and gene expression is correlated and conserved across tissues and vertebrate species^[@CR34]^. Furthermore, modulation of methylation at CpG sites within the human genome can result in an epigenetic pattern that is specific to individual environmental exposures, and these may contribute to disease^[@CR26],[@CR35]--[@CR37]^. For example, environmental factors such as drugs, alcohol, stress, nutrition, bacterial infection, and exercise^[@CR36],[@CR38]--[@CR41]^ have been associated with methylation changes. A number of these methylation changes have been shown to endure and induce lasting biological changes^[@CR36]^, whereas others are dynamic and transient. For example, alcohol consumption affects genome-wide methylation patterns in a severity-dependent manner^[@CR42]^ and some of these changes revert upon abstinence from alcohol consumption^[@CR43]^. A similar observation is reported for former tobacco smokers, with DNA methylation changes after cessation eventually reaching levels close to those who had never smoked tobacco^[@CR44]^. Thus, DNA methylation can be indicative of a particular environmental exposure, shed light on the dynamic interaction between the environment and the genome, and provide new insights in to the biological response.

Recreational drug use (an environmental stimulus) has been associated with adverse mental health outcomes, particularly in youth^[@CR45]--[@CR49]^, and epigenetics may play a role in mediating the biology involved. Therefore, we sought to determine whether regular cannabis users displayed differential cytosine methylation compared with non-cannabis users. Cannabis users in this study are participants from the Christchurch Health and Development Study (CHDS), a longitudinal study of a birth cohort of 1265 children born in 1977 in Christchurch, New Zealand. Users often consume cannabis in combination with tobacco. Unusually, the CHDS cohort contains a subset of cannabis users who have never consumed tobacco, thus enabling an investigation of the specific effects of cannabis consumption, in isolation, on DNA methylation in the human genome.

Methods {#Sec2}
=======

Cohort and study design {#Sec3}
-----------------------

The Christchurch Health and Development Study includes individuals who have been studied on 24 occasions from birth to the age of 40 (*n* = 987 at age 30, with blood collected at approximately age 28). In the early 1990s, research began into the initiation and consequences of cannabis use amongst CHDS participants; cannabis use was assessed prospectively over the period up to the collection of DNA^[@CR11]--[@CR14],[@CR48]--[@CR54]^. A subset of *n* = 96 participants for whom a blood sample was available are included in the current study. Cases (regular cannabis users, *n* = 48) were matched with controls (*n* = 48) for sex (*n* = 37 male, *n* = 11 female each group, for additional information see Supplementary Table [1](#MOESM1){ref-type="media"}). Case participants were partitioned into two subsets: one that contained cannabis-only users (who had never consumed tobacco, "cannabis-only", *n* = 24 \[*n* = 21 male, *n* = 3 female\]), and one that contained cannabis users who also consumed tobacco ("cannabis with tobacco", *n* = 24 \[*n* = 16 male, *n* = 8 female\]) and were selected on the basis that they either met DSM-IV^[@CR55]^ diagnostic criteria for cannabis dependence, or had reported using cannabis on a daily basis for a minimum of three years, prior to age 28. Of the 48 cannabis users, 6 participants had ceased cannabis use by 28 years of age, however, still met the diagnostic criteria for cannabis dependence. Mode of cannabis consumption was via smoking, for all participants. The median duration of regular use was 9 years (range 3--14 years). Control participants had never used cannabis or tobacco. In addition, comprehensive single nucleotide polymorphism (SNP) data was available for all participants^[@CR56]^. All aspects of the study were approved by the Southern Health and Disability Ethics Committee, under application number CTB/04/11/234/AM10 "Collection of DNA in the Christchurch Health and Development Study", and the CHDS ethics approval covering collection of cannabis use: "16/STH/188/AM03 The Christchurch Health and Development Study 40 Year Follow-up".

DNA extraction and methylation arrays {#Sec4}
-------------------------------------

DNA was extracted from whole blood using the KingFisher Flex System (Thermo Scientific, Waltham, MA, USA), as per the published protocols. DNA was quantified via NanoDrop^TM^ (Thermo Scientific, Waltham, MA, USA) and standardised to 100 ng/μl. Equimolar amounts were shipped to the Australian Genomics Research Facility (AGRF, Melbourne, VIC, Australia) for analysis with the Infinium® MethylationEPIC BeadChip (Illumina, San Diego, CA, USA).

Bioinformatics and statistics {#Sec5}
-----------------------------

All analysis was carried out using R (Version 3.5.2^[@CR57]^). Prior to normalisation, quality control was performed on the raw data. Firstly, sex chromosomes and 150 failed probes (detection *P* value \> 0.01 in at least 50% of samples) were excluded from analysis. Furthermore, potentially problematic CpGs with adjacent SNVs, or that did not map to a unique location in the genome^[@CR58]^, were also excluded, leaving 700,296 CpG sites for further analysis. The raw data were then normalised with the NOOB procedure in the minfi package^[@CR59]^ (Supplementary Fig. [1](#MOESM1){ref-type="media"}). Normalisation was checked by visual inspection of intensity densities and the first two components from Multi-Dimensional Scaling of the 5000 most variable CpG sites (Supplementary Figs. [2](#MOESM1){ref-type="media"} and [3](#MOESM1){ref-type="media"}). The proportions of cell types (CD4+, CD8+ T cells, natural killer, B cells, monocytes and granulocytes) in each sample were estimated with the Flow.Sorted.Blood package^[@CR60]^. Linear models were fitted to the methylated/unmethylated or M ratios using limma^[@CR61]^. Separate models were fitted for cannabis-only vs. controls, and cannabis plus tobacco users vs. controls. Both models contained covariates for sex (bivariate), socioeconomic status (three levels), batch (bivariate), population stratification (four principal components from 5000 most variable SNPs) and cell type (five continuous). *β* values were calculated, defined as the ratio of the methylated probe intensity (M)/the sum of the overall intensity of both the unmethylated probe (U) + methylated probe (M). *P* values were adjusted for multiple testing with the Benjamini and Hochberg method and assessed for genomic inflation with bacon^[@CR62]^. Differentially methylated CpG sites that were intergenic were matched to the nearest neighbouring genes in Hg19 using GRanges^[@CR63]^, and the official gene symbols of all significantly differentially methylated CpG sites (nominal *P* \< 0.001) in cannabis-only users were tested for enrichment in KEGG 2019 human pathways with EnrichR^[@CR64]^.

Results {#Sec6}
=======

Data normalisation {#Sec7}
------------------

Modelled effects showed no indication of genomic inflation with *λ* = 1.04 for cannabis-only users (Supplementary Fig. 4a) and *λ* = 0.855 for cannabis with tobacco users (Supplementary Fig. 4b), versus controls. These were confirmed with bacon for cannabis-only (inflation = 0.98, bias = 0.044) and cannabis with tobacco users (inflation = 0.91, bias = 0.19). Inflation values \<1 suggest that the results may be conservative.

Cannabis with tobacco users had a significantly lower estimated proportion of natural killer cells than controls (1.8%, 0.4--3.2%, *P* \< 0.014) with no other proportions differing significantly. After adjusting for multiple comparisons this was not significant (*P* = 0.08), however, we note that it is consistent with other findings that NK-cells are suppressed in the plasma of tobacco smokers^[@CR65],[@CR66]^.

Differential methylation {#Sec8}
------------------------

The most differentially methylated CpG sites for cannabis users relative to controls differed in the absence (Table [1](#Tab1){ref-type="table"}) and presence (Table [2](#Tab2){ref-type="table"}) of tobacco smoking. Five individual CpG sites were significantly differentially methylated (*P* adjusted \<0.008) between cannabis users and controls when cannabis with tobacco was used (Table [2](#Tab2){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). The top CpG sites in the *AHRR, ALPG* and *F2RL3* genes (Table [2](#Tab2){ref-type="table"}) are consistent with previous studies on tobacco use without cannabis (e.g. refs. ^[@CR44],[@CR67]--[@CR69]^), and cg17739917 is in the same CpG-island as other CpGs previously shown to be hypomethylated in response to tobacco^[@CR70]^. Cannabis-only users showed no CpG sites differentially methylated after correction for multiple testing (Table [1](#Tab1){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}), however, the most differentially methylated site was hypermethylation of cg12803068 in the gene *MYO1G*, which has been reported to be hypermethylated in response to tobacco use^[@CR67]^. We identified 28 genes with multiple (two or more) differentially methylated CpG probes (Supplementary Table [2](#MOESM1){ref-type="media"}). Of these 28 genes, 25 have all sites hypermethylated, one has two sites hypomethylated, two have one hypermethylated and one hypomethylated probe.Table 1Top 15 differentially methylated CpG sites in cannabis-only users vs controls.CpGGeneLocationDistanceCannabisControlDifference*P* value*P* value(bp)*β*~U~*β*~C~*β*~U~ − *β*~C~NominalAdjustedcg12803068MYO1GIntron0.80.710.16.30E−070.4cg02234936ARHGEF1Intron0.140.130.011.10E−060.4cg01695406TMEM190Intron0.820.770.053.00E−060.6cg24875484MUCL3Intron0.10.090.013.90E−060.6cg05009104MYO1GIntron0.790.740.055.90E−060.6cg00470351CDC20Exon0.40.380.026.10E−060.6cg24060040DUS3LUpstream11,0180.110.080.036.30E−060.6cg12322720FOXB1Downstream150,9210.580.520.068.90E−060.7cg16746471KIAA1324LPromoter3740.10.080.021.10E−050.7cg04180046MYO1GIntron0.560.520.041.20E−050.7cg06955687DDX25Downstream28,7690.740.70.041.20E−050.7ch.22.707049RTNRC6BDownstream159,7370.060.040.011.30E−050.7cg09344183SP9Downstream59640.060.050.011.40E−050.7cg06693983TMEM190Exon0.840.760.081.40E−050.7cg26069230ADAP2Exon0.160.140.011.50E−050.7Beta values with *P* values, nominal and adjusted by the Benjamini and Hochberg method. Locations are relative to hg19 with gene names for overlapping genes or nearest 5ʹ gene with distance to the 5ʹ end shown.Table 2Top 15 differentially methylated CpG sites in cannabis with tobacco users vs controls.CpGGeneLocationDistanceCannabisControlDifference*P* value*P* value(bp)*β*~U~*β*~C~*β*~U~ − *β*~C~NominalAdjustedcg05575921AHRRIntron0.660.89−0.241.40E−110.00001cg21566642ALPGDownstream13,1090.440.62−0.179.90E−110.00003cg03636183F2RL3Exon0.590.68−0.092.60E−090.0006cg01940273ALPGDownstream13,3820.530.63−0.093.60E−080.00636cg17739917RARAIntron0.370.47−0.15.60E−080.00783cg01541424LINC02393Upstream491,5080.170.130.046.30E−070.07cg12828729TIFABUpstream35,8800.560.50.067.10E−070.07cg10148067MTFR1Upstream39280.910.880.027.70E−070.07cg14391737PRSS23Intron0.360.42−0.069.60E−070.07cg07219494TENM2Upstream303,3590.70.75−0.051.40E−060.1cg05723029PIEZO2Intron0.830.790.051.50E−060.1cg03329539ALPGDownstream11,7770.360.41−0.053.20E−060.2cg24994593LDLRAD3Intron0.90.890.024.20E−060.2cg25009999LINC01168Downstream14,1520.930.920.015.60E−060.3cg13957017TTLL6Intron0.720.690.037.30E−060.3Beta values with *P* values, nominal and adjusted by the Benjamini and Hochberg method. Locations are relative to hg19 with gene names for overlapping genes or nearest 5ʹ gene with distance to the 5ʹ end shown.Fig. 1A Manhattan plot of the genome-wide CpG sites found in the cannabis with tobacco analysis.The *Y* axis presents −log10(*p*) values with the most significantly differentially methylated sites labelled with the gene the CpG site resides in.Fig. 2A Manhattan plot of the genome-wide CpG sites found in the cannabis-only analysis.The *Y* axis presents −log10(*p*) values with the most nominally significantly differentially methylated sites labelled with the gene the CpG site resides in. NB, where a gene name is near multiple points, the appropriate point is circled in black.

To describe the data we chose a nominal *P* value of 0.001, and observed that both cannabis-only and cannabis with tobacco users showed relatively higher rates of hypermethylation than hypomethylation compared with controls and that the distribution of these CpG sites was similar with respect to annotated genomic features (Table [3](#Tab3){ref-type="table"}). Four CpG sites overlapped between the cannabis-only and cannabis with tobacco users analyses; two were hypermethylated; cg02514528, in the promoter of *MARC2*, and cg27405731 in *CUX1*, and one, cg26542660 in the promoter of *CEP135*, was hypomethylated in comparison to controls. The second most differentially methylated site (ranked by *P* value) in cannabis-only users was cg02234936 which maps to *ARHGEF1*; this was hypermethylated in the cannabis with tobacco users.Table 3Summary of CpG sites from cannabis-only and cannabis with tobacco users vs. non-users.Cannabis-onlyTobacco + CannabisBothDifferentially methylated loci (FWER = 0.05)06Differentially methylated loci (*P* \< 0.001)Total521533Hypermethylated42080.6%40375.6%2Hypomethylated10119.4%13024.4%1Hyper (cannabis) Hypo (cannabis + tobacco)1*Location*Intron21641.5%26449.5%Exon9718.6%6512.2%Exon Boundary00Promoter8917.1%6011.3%3ʹ UTR30.6%10.2%5ʹ UTR003ʹ (downstream)6211.9%7614.3%5ʹ (upstream)5410.4%6712.6%Counts of significant sites at *P* = 0.001 and at a Benjamini and Hochberg adjusted *P* \< 0.05. 'Both' indicates the number of CpG sites of each type that are present and shared across both analyses.*FWER* family-wise error rate.

Pathway enrichment analyses {#Sec9}
---------------------------

We then took the genes containing differentially methylated CpG sites at *P* \< 0.001 for the cannabis-only group, or the closest gene where that CpG was intergenic (Supplementary Table [3](#MOESM1){ref-type="media"}) and compared them with human KEGG pathways using Enrichr. The hypermethylated CpG sites (*n* = 420) showed enrichment in the arrhythmogenic right ventricular cardiomyopathy, long-term potentiation, cAMP signalling, adrenergic signalling in cardiomyocytes, glutamatergic synapse, hypertrophic cardiomyopathy, dilated cardiomyopathy and nicotine addiction pathways at an adjusted *P* \< 0.05 (Fig. [3](#Fig3){ref-type="fig"}). Enrichment analysis of hypomethylated loci (*n* = 101) in cannabis-only users did not identify any KEGG pathways at or near adjusted significance (*P* \> 0.05, Fig. [4](#Fig4){ref-type="fig"}). We further submitted all differentially methylated CpG sites (hyper and hypomethyated) at a nominal *P* \< 0.001 to Enrichr, revealing significant enrichment for genes involved in the glutamatergic synapse (adjusted *P* = 0.012), arrhythmogenic right ventricular cardiomyopathy (adjusted *P* = 0.011) and long-term potentiation pathways (adjusted *P* = 0.039) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 3Genetic networks enriched within the hypermethylated CpG sites identified in the cannabis-only analysis.Pathways from KEGG 2019. Genes shown by filled cells are hypermethylated in cannabis-only users and included in named pathway.Fig. 4Genetic networks enriched within the hypomethylated CpG sites identified in the cannabis-only users.Pathways from KEGG 2019. Genes shown by filled cells are hypomethylated in cannabis-only users and included in named pathway.Fig. 5Genetic networks enriched within the hypomethylated or hypermethylated CpG sites identified in the cannabis-only users.Pathways from KEGG 2019. Genes shown by filled cells are hypomethylated in cannabis-only users and included in named pathway.

Discussion {#Sec10}
==========

Many countries have recently adopted, or are considering, lenient polices regarding the personal use of cannabis^[@CR71]--[@CR73]^. This approach is supported by the evidence that the prohibition of cannabis can be harmful^[@CR53]^. Further, the therapeutic benefits of cannabis are gaining traction, most recently as an opioid replacement therapy^[@CR74]^. However, previous studies, including analyses of the CHDS cohort, have reported an association between cannabis use and poor health outcomes, particularly in youth^[@CR75],[@CR76]^. Epigenetic mechanisms, including DNA methylation, provide the interface between the environment (e.g. cannabis exposure) and genome. Therefore, we investigated whether changes in an epigenetic mark, DNA methylation, were altered in cannabis users, versus controls, a comparison made possible by the deep phenotyping of the CHDS cohort with respect to cannabis use, and the fact that the widespread practice of mulling or mixing cannabis with tobacco, is not common in New Zealand.

Consistent with previous reports of tobacco exposure, we observed greatest differential methylation in cannabis with tobacco users in the *AHRR* and *F2RL3* genes^[@CR44],[@CR67]--[@CR69]^. These changes, however, were not apparent in the cannabis-only data. Only two nominally significantly differentially methylated (*P* \< 0.05) CpG sites were observed in both the cannabis-only and cannabis with tobacco analyses. This suggests that tobacco may have a more pronounced effect on DNA methylation and/or dominates any effects of cannabis on the human blood methylome, and that caution should be taken when interpreting similar cannabis exposure studies which do not, or cannot, exclude tobacco smokers. Interestingly, the two nominally significant CpG sites (*P* \< 0.05) that overlap between the cannabis-only and the cannabis with tobacco data are located within the *MARC2* and *CUX1* genes, which both have reported roles in brain function; a SNP in *MARC2* has been provisionally associated with the biological response to antipsychotic therapy in schizophrenia patients^[@CR77]^, and the *CUX1* gene has an established role in neural development^[@CR78]^.

Cannabis affects the brain, leading to perceptual alterations, euphoria and relaxation^[@CR18]^, and prolonged use is associated with mood disorders, including adult psychosis^[@CR7],[@CR8],[@CR49],[@CR79],[@CR80]^, mania^[@CR13]^, and depression^[@CR12]^. We did not detect significantly differentially methylated loci associated with exclusive cannabis use at the epigenome-wide level. However, an assessment of those top loci reaching nominal significance (*P* \< 0.05) identified CpG sites within genes involved in brain function and mood disorders, including *MUC3L*^[@CR81],[@CR82]^*, CDC20*^[@CR83]^*, DUS3L*^[@CR84]^*, TMEM190*^[@CR85]^*, FOXB1*^[@CR86]--[@CR88]^*, KIAA1324L/GRM3*^[@CR82],[@CR89]--[@CR94]^*, DDX25*^[@CR81],[@CR95],[@CR96]^*, TNRC6B*^[@CR97],[@CR98]^ and *SP9*^[@CR99]^.

Pathway enrichment revealed that differential methylation in cannabis-only users was over-represented in genes associated with neural signalling and cardiomyopathies. This is consistent with the literature which raises clinical concerns around cardiac complications potentially associated with cannabis use^[@CR100]--[@CR103]^. The enrichment of genes associated with neural signalling pathways is also consistent with the literature, including previous analyses of the CHDS cohort, which report associations between cannabis exposure and brain related biology such as mood disorders^[@CR7],[@CR12],[@CR48],[@CR49],[@CR51]--[@CR54],[@CR104],[@CR105]^. Our study was limited by sample size, achieving \~10% power at *P* = 10^−7^ to detect the largest standardised effect size found. However, while we have not implicated any gene at the genome-wide significance level with respect to differential methylation associated with cannabis-only exposure, our data are suggestive of a role for DNA methylation in the biological response to cannabis, a possibility which definitely warrants further investigations in larger cohorts.

In summary, while tobacco use has declined on the back of state-sponsored cessation programmes^[@CR106]^, rates of cannabis use remain high in New Zealand and globally, and might be predicted to increase further with the decriminalisation or legalisation of cannabis use for therapeutic and/or recreational purposes^[@CR107]^. Therefore, analysis of the potential effects of cannabis (an environmental stimuli) on DNA methylation, an epigenetic mechanism, is timely. Our data are suggestive of a role for DNA methylation in the biological response to cannabis, significantly contributes to the growing literature studying the biological effects of heavy cannabis use, and highlights areas of further analysis in particular with respect to the epigenome.
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